MONICA SAMUEL AVILA GRINBERG
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina
13 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 13
conferenceObject Vaccine-Induced Coronay Antibodie-Mediated Rejection and Thrombosis in a Heart Transplant Pacient: A Case Report(2022) BARROSO, N. D.; GALBIATI, L. C.; ARAGAO, C.; FERNANDEZ, M. P.; AVILA, M. S.; SEGURO, L. F.; MARCONDES-BRAGA, F. G.; MANGINI, S.; CAMPOS, I. W.; OLIVEIRA, J. Junior de; FURQUIM, S.; PIERI, R.; GAIOTTO, F.; BACAL, F.- Brazilian Society of Cardiology Guideline on Myocarditis-2022(2022) MONTERA, Marcelo Westerlund; MARCONDES-BRAGA, Fabiana G.; SIMOES, Marcus Vinicius; MOURA, Lidia Ana Zytynski; FERNANDES, Fabio; MANGINE, Sandrigo; OLIVEIRA JUNIOR, Amarino Carvalho de; SOUZA, Aurea Lucia Alves de Azevedo Grippa de; IANNI, Barbara Maria; ROCHITTE, Carlos Eduardo; MESQUITA, Claudio Tinoco; AZEVEDO FILHO, Clerio F. de; FREITAS, Dhayn Cassi de Almeida; MELO, Dirceu Thiago Pessoa de; BOCCHI, Edimar Alcides; HOROWITZ, Estela Suzana Kleiman; MESQUITA, Evandro Tinoco; OLIVEIRA, Guilherme H.; VILLACORTA, Humberto; ROSSI NETO, Joao Manoel; BARBOSA, Joao Marcos Bemfica; FIGUEIREDO NETO, Jose Albuquerque de; LUIZ, Louise Freire; HAJJAR, Ludhmila Abrahao; BECK-DA-SILVA, Luis; CAMPOS, Luiz Antonio de Almeida; DANZMANN, Luiz Claudio; BITTENCOURT, Marcelo Imbroise; GARCIA, Marcelo Iorio; AVILA, Monica Samuel; CLAUSELL, Nadine Oliveira; JR, Nilson Araujo de Oliveira; SILVESTRE, Odilson Marcos; SOUZA, Olga Ferreira de; MOURILHE-ROCHA, Ricardo; KALIL FILHO, Roberto; AL-KINDI, Sadeer G.; RASSI, Salvador; ALVES, Silvia Marinho Martins; FERREIRA, Silvia Moreira Ayub; RIZK, Stephanie Itala; MATTOS, Tiago Azevedo Costa; BARZILAI, Vitor; MARTINS, Wolney de Andrade; SCHULTHEISS, Heinz-Peter
conferenceObject Anatomopathological Consequences of the Change in the Clinical-Demographic Profile of Chagasic Patients Who Are Candidates for Heart Transplantation in Recent Years(2022) ARAGAO, C. A.; CAMPOS, I. W.; DUARTE, N.; FURQUIM, S.; GALBIATI, L. C.; PEREZ, M.; PIERI, R.; GRINBERG, M. S. Avila; SEGURO, L. F.; MARCONDES-BRAGA, F. G.; MANGINI, S.; STRABELLI, T. M.; GAIOTTO, F. A.; BACAL, F.- Is There a Role for Telemonitoring in Heart Failure?(2022) AVILA, Monica Samuel; BELFORT, Deborah de Sa Pereira
conferenceObject Comparative Survival Analysis Between Azathioprine and Mykophenolate in Chagasic Patients Undergoing Heart Transplantation(2022) FURQUIM, S.; ARAGAO, C. A.; GALBIATI, L. C.; CAMPOS, I. W.; SEGURO, L. F.; MARCONDES-BRAGA, F. G.; GAIOTTO, F. A.; MANGINI, S.; STRABELLI, T. M.; GRINBERG, M. S. Avila; BACAL, F.- Early reduction of pulmonary arterial hypertension in patients using a long-term mechanical ventricular assistance device: a cross-sectional(2022) RANGEL, Bruno Soares da Silva; BISELLI, Bruno; QUINTANILHA, Nadia Romanelli; AVILA, Monica Samuel; PEGO-FERNANDES, Paulo Manuel; JATENE, Fabio Biscegli; KALIL FILHO, Roberto; FERREIRA, Silvia Moreira AyubBACKGROUND: Severe pulmonary arterial hypertension (PAH) is a contraindication for heart transplantation (HT). It has been correlated with increased early and late mortality, mainly associated with right ventricular failure. Ventricular assistance devices (VADs) can promote reduction of intracardiac pressures and consequent reduction of PAH over the medium and long terms, thus enabling future candidature for HT. The diminution of early pulmonary pressure within this scenario remains unclear. OBJECTIVE: To evaluate the reduction of PAH and correlate data from right catheterization with the earliness of this reduction. DESIGN AND SETTING: Cross-sectional study in a general hospital in Sao Paulo, Brazil. METHODS: This was a retrospective analysis on the medical records of patients undergoing VAD implantation in a single hospital. Patients for whom VAD had been indicated as a bridge to candidature for HT due to their condition of constant PAH were selected. RESULTS: Four patients with VADs had constantly severe PAH. Their mean pulmonary artery systolic pressure (PASP) before VAD implantation was 66 mmHg. Over the 30-day period after the procedure, all the patients evolved with a drop in PASP to below 60 mmHg. Their new average was 36 mmHg, which was a drop of close to 50% from baseline values. The one-year survival of this sample was 100%. CONCLUSION: VAD implantation can reduce PAH levels. Early reduction occurred in all patients. Thus, use of VAD is an important bridge tool for enabling candidature for HT among patients with constantly severe PAH.
conferenceObject Multimodality Approach for Surveillance of Cardiac Sarcoidosis After Heart Transplantation Based on a Case Series(2022) BARROSO, N. D.; GALBIATI, L. C.; ARAGAO, C.; FERNANDEZ, M. P.; FURQUIM, S.; PIERI, R.; JD, Junior; MARCONDES-BRAGA, F. G.; MANGINI, S.; AVILA, M. S.; SEGURO, L.; CAMPOS, I. W.; GAIOTTO, F.; BACAL, F.- Plasma biomarkers reflecting high oxidative stress in the prediction of myocardial injury due to anthracycline chemotherapy and the effect of carvedilol: insights from the CECCY Trial(2022) WANDERLEY, M. R. de Barros; ÁVILA, M. S.; FERNANDES-SILVA, M. M.; CRUZ, F. das Dores; BRANDãO, S. M. G.; RIGAUD, V. O. C.; HAJJAR, L. A.; FILHO, R. K.; CUNHA-NETO, E.; BOCCHI, E. A.; AYUB-FERREIRA, S. M.Background: Anthracycline (ANT) is often used for breast cancer treatment but its clinical use is limited by cardiotoxicity (CTX). CECCY trial demonstrated that the β-blocker carvedilol (CVD) could attenuate myocardial injury secondary to ANT. Mieloperoxydase (MPO) is a biomarker of oxidative stress and galectin-3 (Gal-3) is a biomarker of fibrosis and cardiac remodeling. We evaluated the correlation between MPO and Gal-3 behavior with CTX. Materials and Methods: A post hoc analysis was performed in the patients who were included in the CECCY trial. A total of 192 women had her blood samples stored during the study at –80°C until the time of assay in a single batch. Stored blood samples were obtained at baseline, 3 and 6 months after randomization. We excluded samples from 18 patients because of hemolysis. MPO and Gal-3 were measured using Luminex xMAP technology through MILLIPLEX MAP KIT (Merck Laboratories). Results: 26 patients (14.9%) had a decrease of at least 10% in LVEF at 6 months after the initiation of chemotherapy. Among these, there was no significant difference in the MPO and Gal-3 when compared to the group without drop in LVEF (p = 0.85 for both MPO and Gal-3). Blood levels of MPO [baseline: 13.2 (7.9, 24.8), 3 months: 17.7 (11.1, 31.1), 6 months: 19.2 (11.1, 37.8) ng/mL] and Gal-3 [baseline: 6.3 (5.2, 9.6), 3 months: 12.3 (9.8, 16.0), 6 months: 10.3 (8.2, 13.1) ng/mL] increased after ANT chemotherapy, and the longitudinal changes were similar between the placebo and CVD groups (p for interaction: 0.28 and 0.32, respectively). In an exploratory analysis, as there is no normal cutoff value established for Gal-3 and MPO in the literature, the MPO and Gal-3 results were splited in two groups: above and below median. In the placebo group, women with high (above median) baseline MPO blood levels demonstrated a greater increase in TnI blood levels than those with low baseline MPO blood levels (p = 0.041). Compared with placebo, CVD significantly reduced TnI blood levels in women with high MPO blood levels (p < 0.001), but did not reduce the TnI levels in women with low baseline MPO blood levels (p = 0.97; p for interaction = 0.009). There was no significant interaction between CVD treatment and baseline Gal-3 blood levels (p for interaction = 0.99). Conclusions: In this subanalysis of the CECCY trial, MPO and Gal-3 biomarkers did not predict the development of CTX. However, MPO blood levels above median was associated with more severe myocardial injury and identified women who were most likely to benefit from carvedilol for primary prevention (NCT01724450). © 2022 Wanderley Jr. et al.
conferenceObject Challenges in Heart Transplantation During COVID-19 Pandemic in Brazil(2022) BARROSO, N. D.; GALBIATI, L. C.; ARAGAO, C.; AVILA, M. S.; MARCONDES-BRAGA, F. G.; SEGURO, L.; MANGINI, S.; CAMPOS, I. W.; PIERI, R.; FURQUIM, S.; JUNIOR, J. d.; PEREZ, M.; PAULO, A. De; DUQUE, A.; BARBOSA, M.; OHE, L. A.; GAIOTTO, F.; BACAL, F.conferenceObject Influence of Probiotic Supplementation in Inflammatory Profile of Patients with Heart Failure - Study PROBHF: A Clinical Trial, Randomized, Double-Blind, Placebo-Controlled(2022) GOMES, T. T.; MANGINI, S.; MARCONDES-BRAGA, F. G.; AVILA, M. S.; CAMPOS, I. W.; SANTOS, F. B.; SEGURO, L. F.; BACAL, F.